Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study

Journal of the National Cancer Institute

Volumn 104, Issue 17, 2012, Pages 1293-1305

  Bowles, Erin J Aiello ^a   Wellman, Robert ^a   Feigelson, Heather Spencer ^b   Onitilo, Adedayo A ^c   Freedman, Andrew N ^d   Delate, Thomas ^b   Allen, Larry A ^e   Nekhlyudov, Larissa ^f,g   Goddard, Katrina A B ^h   Davis, Robert L ⁱ   Habel, Laurel A ^j   Yood, Marianne Ulcickas ^k   McCarty, Catherine ^c,l   Magid, David J ^b   Wagner, Edward H ^a  

^a CENTER FOR HEALTH STUDIES   (United States)

^b KAISER PERMANENTE   (United States)

^c MARSHFIELD CLINIC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^h CENTER FOR HEALTH RESEARCH   (United States)

ⁱ KAISER PERMANENTE   (United States)

^j DIVISION OF RESEARCH   (United States)

^k HENRY FORD HOSPITAL   (United States)

^l ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CARDIOMYOPATHY; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84866060182     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs317     Document Type: Article

References (41)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology\-v.2.2011, Breast Cancer. Fort Washington, PA: NCCN; 2011. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed April 20, 2011.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. (Pubitemid 17231334)
4. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohisto-chemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-69. (Pubitemid 38821193)
5. Koninki K, Tanner M, Auvinen A, Isola J. HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Res. 2009;11(3):R37.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684. (Pubitemid 41464706)
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672. (Pubitemid 41464705)
8. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of tras-tuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
9. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29(34):4491-4497.
10. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.
11. Ackland S P, Anton A, Breitbach G P, et al. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. J Clin Oncol. 2001;19(4):943-953. (Pubitemid 32176268)
12. Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005;16(6):899-908. (Pubitemid 40903915)
13. Levine MN, Pritchard KI, Bramwell VH, et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophos-phamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol. 2005;23(22):5166-5170. (Pubitemid 46224025)
14. Martin M, Villar A, Sole-Calvo A, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol. 2003;14(6):833-842. (Pubitemid 36827198)
15. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophospha-mide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416-3421.
16. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxo-rubicin and cyclophosphamide followed by paclitaxel with or without tras-tuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231-1238.
17. Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-3428.
18. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25(25):3859-3865. (Pubitemid 47477261)
19. Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epi-rubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol. 2010;28(9):1473-1480.
20. Mackey JR, Clemons M, Cote MA, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15(1):24-35.
21. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684-692.
22. Martin M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist. 2009;14(1):1-11.
23. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracy-cline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808-3815. (Pubitemid 47477254)
24. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23(34):8597-8605. (Pubitemid 46211501)
25. Du XL, Xia R, Liu CC, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009;115(22):5296-5308.
26. Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr. 2005;35:3-11.
27. Surveillance Epidemiology and End Results. http://seer.cancer.gov/. Accessed May 4, 2012.
28. Hornbrook MC, Hart G, Ellis JL, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr. 2005;35:12-25.
29. Delate T, Bowles EJ, Pardee R, et al. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012;21(4):673-680.
30. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296(17):2105- 2111. (Pubitemid 44664705)
31. Allen LA, Yood MU, Wagner EH, et al. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer [published online ahead of print May 25, 2012]. Medical Care. doi:10.1097/MLR.0b013e31825a8c22.
32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
33. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
34. Breslow NE. Discussion of Professor Cox's paper. J Royal Stat Soc B. 1972;34:216-217.
35. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;20:187-220.
36. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19(5):1455-1461. (Pubitemid 32202553)
37. Mullins CD, Montgomery R, Tunis S. Uncertainty in assessing value of oncology treatments. Oncologist. 2010;15(suppl 1):58-64.
38. Blumle A, Meerpohl JJ, Rucker G, Antes G, Schumacher M, von Elm E. Reporting of eligibility criteria of randomised trials: cohort study comparing trial protocols with subsequent articles. BMJ. 2011;342:d1828.
39. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy. 1999;4(2):112-121. (Pubitemid 29186862)
40. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24(25):4107-4115. (Pubitemid 46622286)
41. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006;113(23):2713-2723. (Pubitemid 43947989)